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012.09.00Abstract Aim of the work: To further investigate the possible role of IL-18 in the pathogenesis of
systemic lupus erythematosus (SLE) and development of lupus nephritis (LN), and to explore its
relationship with pathological classes of LN, degree of acute renal activity and chronic damage.
Patients and methods: Forty-one SLE patients with LN, thirty-one lupus non-nephritis patients
and ﬁfteen age and sex matched healthy controls were enrolled in this study. SLE patients were sub-
jected to disease activity assessment by SLEDAI, renal disease activity assessment by the Systemic
Lupus International Collaborating Clinics (SLICC) Renal Activity Score, laboratory investigations
including measurement of serum interleukin-18 using Enzyme Linked Immunosorbent Assay.
Renal biopsy was obtained from LN patients and pathological classiﬁcation was made according
to World Health Organization (WHO) criteria. Analysis of activity and chronicity indices was done
on these biopsy specimens.
Results: Serum levels of IL-18 were signiﬁcantly higher in patients with LN than lupus non-
nephritis patients and healthy controls (p< 0.001). There were signiﬁcant correlations between
IL-18 and SLEDAI (p= 0.002), proteinuria (p= 0.027), renal activity score (p= 0.003) and activ-
ity index (p= 0.039) in patients with LN. There was no signiﬁcant difference in the serum levels of
IL-18 between WHO classes of LN.eumatology & Rehabilitation
ospitals, El-Gomhorrea St.,
, mobile: +20 1222779450.
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46 M.A. Mohsen et al.Conclusion: IL-18 appears to have a pathogenic role in the development of SLE and plays a cru-
cial role in triggering inﬂammation in LN. Serum IL-18 levels could be a useful biomarker to assess
the activity of renal disease in SLE.
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Systemic lupus erythematosus (SLE) is a prototypic autoim-
mune disease with a complex pathogenesis involving multiple
genetic and environmental factors. The disease is characterized
by enhanced autoantibody production, abnormalities in func-
tion of immune-inﬂammatory system and inﬂammatory man-
ifestations in several organs [1].
Lupus nephritis (LN) is a major complication of SLE that
affects 50% of patients. It is mediated by glomerular deposi-
tion of immune complexes that trigger a number of inﬂamma-
tory events leading to tissue damage [2]. The presentation can
range from asymptomatic urinary abnormalities to rapidly
progressive renal failure leading to end-stage renal disease.
Renal failure remains an independent risk factor for death in
patients with LN [3].
Although the etiopathogenesis remains unclear, cytokine-
mediated inﬂammation may occur in SLE [4]. A central path-
ological effect has been described for the inﬂammatory Th1
dependent cytokine IFN-c. Production of IFN-c is ampliﬁed
by the cytokine IL-18, previously known as IFN-c-inducing
factor, in true synergy with other Th1-related cytokines,
IL-2, IL-12, IL-15 and IL-23 [5]. IL-18 which belongs to the
IL-1 cytokine family is predominantly produced by antigen
presenting cells including macrophages and dendritic cells. It
stimulates the production of inﬂammatory cytokines such as
IFN-c, TNF-a and IL-1b, upregulates chemokine production,
enhances expression of adhesion and co-stimulatory molecules,
enhances perforin- and FasL-mediated cytotoxicity by NK
and T cells, and induces the release of matrix metalloprotein-
ases, all activities that are central to the inﬂammatory reaction
and subsequent tissue damage [6].
Accumulating evidence indicates that serum IL-18 levels are
signiﬁcantly elevated and correlated with disease activity in
SLE [7]. Additionally, other studies have reported enhanced
IL-18 renal expression in murine models of LN [8] and ele-
vated levels of IL-18 transcripts in the biopsy specimens of kid-
neys from patients with LN [9]. In contrast, several studies
have reached the opposite conclusions that the levels of serum
IL-18 are irrelevant to disease activity and kidney involvement
[10,11]. Thus, the functions of IL-18 in the pathogenesis of LN
are still debated.
The aim of the present study was to further investigate the
possible role of IL-18 in the pathogenesis of SLE and develop-
ment of LN, and to explore its relationship with WHO patho-
logical classes of LN, degree of acute renal activity and chronic
damage.
2. Patients and methods
2.1. SLE patients and healthy controls
This study was conducted on 72 SLE patients recruited from
the Department of Nephrology at the Mansoura Urology andNephrology Center and Rheumatology and Rehabilitation
Department, Mansoura University, Egypt. Diagnosis of
SLE was established according to the American College of
Rheumatology revised classiﬁcation criteria for SLE [12].
SLE patients were divided into two groups according to the
presence of renal involvement: 31 patients with no renal
affection designated (lupus non-nephritis), and 41 patients
with LN. Patients with LN were deﬁned by persistent pro-
teinuria > 0.5 g/24 h, or the presence of cellular casts, persis-
tent hematuria or renal biopsy results consistent with LN
[13]. Renal ultrasound was done for these patients at the start
of the study to exclude other renal causes of kidney impair-
ment. Patients with any of the following were excluded: dia-
betes mellitus, uncontrolled hypertension, overlap syndrome,
malignancy, and chronic infections. Fifteen age and sex
matched apparently healthy subjects served as control group.
An approval was obtained from the local ethics and scientiﬁc
committees in addition to an informed consent from all par-
ticipants in the study.
SLE patients were subjected to thorough history taking,
general and local examination. Disease activity was assessed
using the SLE Disease Activity Index (SLEDAI) [14]. Renal
disease activity was measured by the Systemic Lupus Interna-
tional Collaborating Clinics (SLICC) Renal Activity Score. It
was calculated as follows; proteinuria 0.5–1 g/day (3 points),
proteinuria 1–3 g/day (5 points), proteinuria > 3 g/day (11
points), urine RBC’s > 5/hpf (3 points), and urine WBC’s >
5/hpf (1 point) [15].
Blood sample (5 ml) was extracted from each subject. Ser-
um was isolated and stored frozen at 80 C for later ELISA
experiment. Laboratory investigations included: full blood
picture, ESR, CRP, serum creatinine, simple urine analysis
& estimation of 24 h urinary protein, urine protein/creatinine
ratio (P/C ratio), ALT, AST, C3, C4, ANA, and anti-
dsDNA. Blood and urine samples were collected on the same
day.2.2. Measurement of serum IL-18
The RayBio Human IL-18 ELISA kit (Cat#: ELH-IL18-001)
was used for the measurement of serum IL-18 [16]. This assay
employs an antibody (ab) speciﬁc for human IL-18 coated on a
96-well plate. 100 ll Standards and samples are pipetted into
the wells and IL-18 present in a sample is bound to the wells
by the immobilized ab. The wells are washed and 100 ll biotin-
ylated anti-human IL-18 ab is added. After washing away
unbound biotinylated ab, 100 ll horseradish peroxidase-conju-
gated streptavidin is pipetted into the wells. The wells are again
washed, 100 ll tetra-methylbenzidine substrate solution is
added to the wells and color develops in proportion to the
amount of IL-18 bound. The Stop Solution (50 ll) changes
the color from blue to yellow, and the intensity of the color
is measured at 450 nm.
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It was obtained from all patients with LN at the start of the
study for pathological classiﬁcation of LN according to the cri-
teria deﬁned by the WHO [17]. The renal histopathological
examination included light microscopic examination and
immunoﬂuorescence. The activity index (AI) and chronicity in-
dex (CI) of each biopsy specimen were also determined accord-
ing to the previously accepted indices [18]. AI is the sum of
semiquantitative manual scores (0–3 each) of the following
parameters: endocapillary hypercellularity; leukocyte inﬁltra-
tion; subendothelial hyaline deposits; interstitial inﬂammation;
ﬁbrinoid necrosis and cellular crescents. Scores of the last two
parameters are counted double, making a total AI of 0–24. CI
is the sum of semiquantitative manual scores (0–3 each) of the
following parameters making a total CI of 0–12: glomerular
sclerosis; ﬁbrous crescents; interstitial ﬁbrosis and tubular
atrophy. Evaluation of the biopsy specimens was performed
by a single pathologist.
Statistics: Statistical analysis was performed using SPSS
version 16.0 software. The description of the data was done
in the form of mean ± standard deviation (SD) for quantita-
tive data, and frequency & proportion for qualitative data.
For quantitative data, ‘‘student’s t-test’’ was used to compare
between two groups, and ‘‘one way ANOVA’’ to compare be-
tween more than two groups, followed by Bonferroni multiple
comparisons. To test the association between variables, Pear-
son correlation co-efﬁciency test was used. P is signiﬁcant if
60.05 at conﬁdence interval of 95%.
3. Results
Baseline characteristics of patients with LN and lupus non-
nephritis patients are shown in Table 1. Fifteen healthy control
subjects (12 females and 3 males, aged 35.92 ± 10.6 years)
were recruited. All the three groups were age and sex matched.
3.1. Serum IL-18 levels in SLE patients
It was found that serum IL-18 levels were signiﬁcantly higher
in patients with LN and in lupus non-nephritis patients than
in healthy controls (156.13 ± 57.96, 112.01 ± 48.23,
56.44 ± 23.59 pg/ml respectively, p< 0.001). Also, patients
with LN had signiﬁcantly higher levels of serum IL-18 than lu-
pus non-nephritis patients (p< 0.001) (Fig. 1). In addition, no
signiﬁcant difference was found in the serum levels of IL-18 be-
tween male and female patients with SLE (160.00 ± 53.31,
132.56 ± 48.19 pg/ml respectively, p= 0.08). No signiﬁcant
correlation was also demonstrated between serum IL-18 levels
and patient’s age, age at disease onset and disease dura-
tion(r= 0.04, 0.09, 0.10 respectively, p> 0.05).
3.2. Association of serum IL-18 levels with disease
manifestations
No signiﬁcant difference was found in serum IL-18 levels be-
tween SLE patients with and without hematological involve-
ment (161.20 ± 49.29, 143.72 ± 49.08 respectively, p=
0.137), with and without arthritis (127.55 ± 41.35, 139.71 ±
42.78 respectively, p= 0.245), or with and without pleuro-pul-monary involvement (137.72 ± 46.52, 134.41 ± 40.22 respec-
tively, P= 0.760). However, SLE patients with central
nervous system (CNS) manifestations (n= 39) in the
form of headache, psychosis and/or seizures had signiﬁcantly
higher serum IL-18 levels than patients without CNS manifes-
tations (177.36 ± 67.08, 128.46 ± 55.28 pg/ml respectively,
p= 0.01). It is worthy to note that 15 patients with CNS
involvement had concomitant renal disease.3.3. Correlation of serum IL-18 levels with SLEDAI, renal
activity score, and laboratory ﬁndings
A signiﬁcant correlation was found between serum IL-18 and
the total SLEDAI score in all SLE patients (r= 0.346,
p= 0.003) and in patients with LN (r= 0.461, p= 0.002),
but not in lupus non-nephritis patients (r= 0.106,
p= 0.572) (Fig. 2). Moreover, a signiﬁcant correlation was
found between serum IL-18 and anti-dsDNA abs titer in 72
SLE patients (r= 0.343, p= 0.003), and in patients with
LN (r= 0.464, p= 0.002), while no signiﬁcant correlation
was demonstrated between them in lupus non-nephritis pa-
tients (r= 0.004, p= 0.981). In addition, a negative signiﬁ-
cant correlation was found between serum IL-18 and C3
(r= -0.5, p= 0.001) and C4 (r= -0.515, p= 0.001) only in
patients with LN, while no signiﬁcant correlation was found
between serum IL-18 and ESR. Regarding laboratory ﬁndings
assessing renal function, serum IL-18 of patients with LN
showed a signiﬁcant correlation with serum creatinine
(r= 0.504, p= 0.001), 24 h urinary protein (r= 0.346,
p= 0.027), and P/C ratio (r= 0.336, p= 0.032) (Table 2),
and renal activity score (r= 0.46, p= 0.003).3.4. Association of serum IL-18 levels with WHO classes of LN
By comparing the serum level of IL-18 in different classes of
LN, it was found that the highest titers of serum IL- 18 were
detected in patients with class IV (167.01 ± 67.41 pg/ml) fol-
lowed by class III (152.53 ± 46.01 pg/ml) then class II
(121.90 ± 60.44 pg/ml) and the least titers were for class V
(107.34 ± 60.66 pg/ml), but the difference was not statistically
signiﬁcant (p= 0.083) (Table 3). A positive signiﬁcant correla-
tion was demonstrated between serum IL-18 and AI of renal
biopsy of patients with LN (r= 0.323, p= 0.039), while no
signiﬁcant correlation was found between serum IL-18 and
CI (r= 0.25, p= 0.115).3.5. Relation between serum IL-18 levels and medications
Patients with LN who received corticosteroids (CS) + cyclo-
phosphamide (CYC) (n= 29) had statistically signiﬁcant high-
er serum IL-18 levels than those who received CS ± other
immunosuppressives (n= 12) (167.22 ± 56.46, 119.16 ±
53.87 pg/ml respectively, p= 0.016). However, no signiﬁcant
correlation was demonstrated between serum IL-18 and
daily dose of prednisolone (r= 0.168, p= 0.294), azathio-
prine (AZA) (r= 0.135, p= 0.549), hydroxychloroquine
(OHCQ) (r= 0.178, p= 0.623) cyclosporine A (CsA)
(r= 0.113, p= 0.790) and number of CYC pulses (r=
0.032, p= 0.841).
Table 1 Baseline characteristics of lupus nephritis and lupus non-nephritis patients.
Variables Patients with lupus nephritis (n= 41) Lupus non-nephritis patients (n= 31) P
Sex (Female/Male) 32/9 28/3 0.21
Age, years (mean ± SD) 32.41 ± 11.57 36.03 ± 12.15 0.20
Duration of the disease (yrs) 4.67 ± 3.86 6.07 ± 6.02 0.23
SLEDAI score (mean ± SD) 24.63 ± 12.92 23.00 ± 9.88 0.56
Renal activity score (mean ± SD) 8.75 ± 4.95
ESR 1st hour (mm/h) 37.37 ± 23.67 34.90 ± 19.80 0.64
C3 (mg/dl) 86.73 ± 36.07 97.39 ± 29.74 0.18
Anti-dsDNA titer (IU/ml) 79.4 2 ± 67.53 59.28 ± 48.40 0.16
Mean serum creatinine (range) mg/dl
WHO Class of LN (n %)





Activity index (/24) (mean ± SD) 10.22 ± 4.11
Chronicity index(/12) (mean ± SD) 2.54 ± 1.21
Treatment with prednisone (n%) 41 (100%) 29 (93.55%)
Daily dose, mg (mean ± SD) 25.61 ± 14.14 15.09 ± 11.62 <0.001
Treatment with NSAIDs (n%) 0 (0%) 5 (16.13%)
Treatment with AZA (n%) 25 (60.98%) 21 (67.74%)
Daily dose, mg (mean ± SD) 81.82 ± 22.07 95.24 ± 26.95
Treatment with OHCQ (n%) 10 (24.39%) 17 (54.84%)
Daily dose, mg (mean ± SD) 380.00 ± 113.53 258.82 ± 93.93 <0.01
Treatment with CsA (n%) 10 (24.39%) 0 (0%)
Daily dose, mg (mean ± SD) 75.00 ± 23.15 0.00
Treatment with CYC (n%) 29 (70.73%) 0 (0%)
Number of pulses 5.10 ± 3.58 0.00
AZA= azathioprine, OHCQ= hydroxychloroquine, CsA = cyclosporin A, CYC= cyclophosphamide.
Figure 1 Comparison between IL18 serum levels in the 3 studied
groups (LN, lupus non-nephritis, and healthy controls) P< 0.001
by ANOVA test.
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SLE is a complex disease driven by the activation of different
lymphokine systems at different time-points, possiblyexplaining the heterogeneity of clinical manifestations [19]. Lu-
pus nephritis is a major contributor to morbidity and mortality
in patients with SLE and up to half of lupus patients develop
LN during the course of their disease [2]. It has recently be-
come evident that abnormal production of Th cell cytokines
and chemokines is primarily involved in kidney damage of
SLE. Increased Th1:Th2 (IFN-c:IL-4) ratio was proposed to
promote renal damage in SLE with predominance of Th1 cyto-
kines in the kidneys of patients with diffuse proliferative LN
[20].
IL-18 previously known as IFN-c-inducing factor was
found to be correlated with disease activity and renal damage
in SLE in both human and animal investigations [8,21]. Upreg-
ulation of this proinﬂammatory cytokine accelerated protein-
uria and caused aggravation of nephritis. Furthermore,
intramuscular vaccination of young MRL/lpr mice with a
cDNA encoding murine IL-18 elicited signiﬁcant reductions
in lymphoproliferation, renal damage and mortality [22]. On
the other hand, some authors have not demonstrated signiﬁ-
cant associations between serum IL-18 and any kind of renal
manifestation in SLE patients [11]. So, there is a conﬂict about
the possible role of IL-18 in the pathogenesis of LN.
Serum IL-18 level was found to be signiﬁcantly higher in
SLE patients with and without LN than that in healthy con-
trols in agreement with several studies [2,4,7,9,13,23–28]. Fur-
thermore, the present results approved previous studies that
serum level of IL-18 was signiﬁcantly higher in patients with
LN than that of lupus non-nephritis patients [2,9,23]. This
suggests the possible role of IL-18 in the pathogenesis of
SLE, in particular LN.
Figure 2 Correlation between serum IL-18 and total SLEDAI score in patients with lupus nephritis and lupus non-nephritis patients.
Pearson correlation co-efﬁciency test–P is signiﬁcant if 60.05. Patients with LN (P= 0.002), lupus non-nephritis patients (P= 0.572).
Table 3 Comparison between the serum levels of IL-18 in
different classes of lupus nephritis patients.
Serum IL-18 (pg/ml)
in LN patients
(n= 41)mean ± SD
P
Class 2 (n= 5) 121.90 ± 60.44 0.083
Class 3 (n= 12) 152.53 ± 46.01
Class 4 (n= 17) 167.01 ± 67.41
Class 5 (n= 7) 107.34 ± 60.66
One way ANOVA test is used.
Table 2 Correlation between serum level of IL-18 and









Serum IL-18 (pg/ml) in
patients with LN
(N= 41)
R 0.504 0.346 0.336
P 0.001 0.027 0.032
Pearson correlation co-efﬁciency test–P is signiﬁcant if 60.05.
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levels of IL-18 in SLE patients [7,9] consistent with our results.
In addition, the present data did not ﬁnd signiﬁcant relations
between serum IL-18 and organ involvement other than the re-
nal system in SLE patients except for CNS involvement. It is
worthy to mention that IL-18 transcript was demonstrated
by RT-PCR in a variety of brain regions in mice [29]. In addi-
tion, it was demonstrated in vitro that microglia and astrocytes
can produce IL-18 and its level can be up-regulated following
lipopolysaccharide stimulation or treatment with INF-c. There
are also some studies that support a function for IL-18 in the
onset and progression of autoimmune CNS disease [30], but its
role in SLE CNS disease needs further research.
Similarly, other studies found no association of IL-18 levels
with organ involvement other than renal disease, so they sug-
gested that the high IL-18 serum titers within their SLE co-
horts were primarily attributable to the occurrence of LN
[2,9]. On the other hand, others did not ﬁnd signiﬁcant associ-
ations between serum IL-18 and any clinical manifestations ofSLE including renal manifestations [10,11]. This may be re-
lated to the small number of SLE patients with renal disease
in their studies.
The present study showed a signiﬁcant correlation between
serum IL-18 and SLE disease activity measured by SLEDAI in
all 72 SLE patients. Upon subgroup analysis, serum IL-18 cor-
related signiﬁcantly with SLEDAI score in patients with LN
but not in lupus non-nephritis patients. This further indicates
that IL-18 played an inﬂammatory role in glomerulonephritis
of SLE patients. This result is in concordance with that of
Wong et al. [23] and in partial agreement with another study
that demonstrated a signiﬁcant correlation of plasma IL18
concentration with SLEDAI score in both renal and non-renal
SLE groups [13]. Like minded, it was demonstrated that the
mean IL-18 level at the active stage (SLEDAI >6) was signif-
icantly higher than that at the stable stage after treatment sug-
gesting that IL-18 might contribute to the ﬂare of the disease
[24].
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18 and anti-dsDNA titer in all SLE patients and in the group
of LN. Moreover, signiﬁcant negative correlations between
serum IL-18 and serum C3 and C4 were demonstrated in pa-
tients with LN while no signiﬁcant correlation was found with
ESR. In another study, serum IL-18 correlated signiﬁcantly
with anti ds-DNA titer in SLE patients during the active stage,
while not signiﬁcantly correlated with the other laboratory
parameters including ESR, C3 and C4 [24]. Hu and coworkers
did not also ﬁnd any signiﬁcant correlation between the serum
IL-18 level in LN patients and ESR or C3 [27]. This inconsis-
tency with our results may be due to lower disease activity than
that of our patients.
The association between serum levels of IL-18 and WHO
pathological classes of LN was further investigated in this
study. It was found that class IV patients had the highest ser-
um IL-18 levels followed by class III then class II and the low-
est were for class V. However, the difference of IL-18 levels
among the pathological classes was not statistically signiﬁcant
as reported previously [27]. Moreover, Shimizu and coworkers
recognized a signiﬁcant increase in the serum levels of IL-18 in
LN Classes II, III and IV versus control however, the serum
level stayed within the non-signiﬁcant range in Class V [28].
Furthermore, in the study by Chen and colleagues, signiﬁcant
higher levels of serum IL-18 were observed in LN patients with
WHO class IV than in those with class III, while there were no
signiﬁcant differences in the serum IL-18 levels between class
III and class V or between class IV and class V [4]. On the
other hand, highest titers of serum IL-18 were demonstrated
in patients with classes IV and V followed by class III and class
II [2,9]. Interestingly, a signiﬁcant correlation between AI (but
not histological CI) and serum IL-18 in LN patients was recog-
nized in this study. This result indicates that the serum level of
IL-18 may be related to the degree of activity of LN within
each class rather than the WHO pathological classiﬁcation of
the disease. Furthermore, the level of ongoing histological
activity may be not correlated with the cumulative histological
injury [28]. Hu and coworkers are partially in agreement with
our results as they did not ﬁnd any signiﬁcant correlation be-
tween serum IL-18 and both AI and CI of renal biopsy in pa-
tients with LN [27]. However, a close positive correlation was
found between IL-18 glomerular expression and IL-18 in urine
of LN patients with AI and not with CI [31–33].
A signiﬁcant correlation between serum IL-18 level and the
SLICC renal activity score was demonstrated. Additionally,
serum IL-18 of patients with LN showed a signiﬁcant correla-
tion with serum creatinine, 24 h urinary protein and P/C ratio.
These results verify that measurement of the serum level of IL-
18 can reﬂect the activity of LN supporting the other labora-
tory tests for assessment of renal function. Consistent with
our results, a signiﬁcant correlation was demonstrated between
serum level of IL-18 and urinary microalbumin [9], and serum
creatinine [25] in SLE patients. On the other hand, other stud-
ies revealed that there were no signiﬁcant correlations between
serum IL-18 levels either with 24-h urine protein levels [27], or
serum creatinine levels [7] in SLE patients. This discrepancy
with our results may stem from different sizes of the cohort
studied, ethnic origin of the patients, and from difference in
the deﬁnitions of renal involvement.
Contrary to usual expectation, it was found that patients
with LN who received CS + CYC had statistically signiﬁcant
higher serum IL-18 levels than those who received CS ± otherimmunosuppressives. This result may be due to higher activity
in our patients with LN receiving CYC. No signiﬁcant correla-
tion was also demonstrated between serum IL-18 and daily
dose of prednisolone, AZA, OHCQ, CsA and number of
CYC pulses in consistent with the results of Wong et al. [23].
Moreover, Robak et al. reported that the serum IL-18 level
was not correlated to the use of drugs as immune inhibitors
[10] suggesting that their elevated concentrations are connected
with the disease itself and not with the effect of treatment.
Other authors’ observations of the effect of SLE treatment on
IL-18 concentrations are divergent as they found a positive cor-
relation existing between IL-18 concentration and glucocorti-
coid dose taken by the patients at examination [25]. This
correlation could not be explained whether it was a direct effect
of CS treatment or simply a reﬂection of the increased SLEDAI
justifying a higher prednisolone dose. Contrary to our results,
two recent studies revealed that patients with LN treated with
prednisone in combination with CYC pulse therapy have sig-
niﬁcantly lower IL-18 levels than those treated without CYC,
but still higher than control, and other immunosuppressive
agents such as high dose CS, AZA and OHCQ tended to lower
this cytokine though the difference was not signiﬁcant [17,27].
In conclusion, IL-18 appears to have a pathogenic role in
the development of SLE, and plays a crucial role in triggering
inﬂammation in LN. Serum IL-18 levels could be a useful bio-
marker to assess the activity of renal disease in SLE. However,
further studies are required to understand the exact mechanism
by which IL-18 contributes to the pathogenesis and activation
of LN.
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